Boothbay Fund Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Boothbay Fund Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-261,933	Closed	-$4.03M	–	2326
2025 Q3	$4.03M	Buy	261,933 +133,088	+103%	+$1.74M	0.06%	368
2025 Q2	$1.21M	Buy	+128,845	New	+$1.42M	0.02%	627
2023 Q4	–	Sell	-76,909	Closed	-$1.12M	–	1957
2023 Q3	$1.12M	Buy	76,909 +404	+0.5%	+$7.64K	0.03%	712
2023 Q2	$1.6M	Buy	+76,505	New	+$1.59M	0.04%	640
2021 Q1	–	Sell	-15,324	Closed	-$341K	–	1767
2020 Q4	$341K	Buy	+15,324	New	+$318K	0.01%	900
2018 Q4	–	Sell	-10,000	Closed	-$81K	–	867
2018 Q3	$81K	Buy	+10,000	New	+$71.3K	0.01%	729
2017 Q3	–	Sell	-15,689	Closed	-$219K	–	752
2017 Q2	$219K	Buy	+15,689	New	+$179K	0.05%	528

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Boothbay Fund Management's SNDX Position: Q4 2025 in Review

Boothbay Fund Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 261,933 shares — an estimated $4.03M sold.

Boothbay Fund Management first reported a position in SNDX in Q2 2017 and held it in 7 quarters. The position peaked at $4.03M in Q3 2025. 229 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

Boothbay Fund Management reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Boothbay Fund Management sold 261,933 Syndax Pharmaceuticals shares in Q4 2025, an estimated $4.03M.
Boothbay Fund Management first reported a position in Syndax Pharmaceuticals in Q2 2017 and held it in 7 quarters.
Boothbay Fund Management's Syndax Pharmaceuticals position peaked at $4.03M in Q3 2025.
229 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.